DP112 | UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN ALL-ORAL TREATMENT

BACKGROUND: Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax. BGB-11417-105 (NCT04973605) is an ongoing phase 1b/2 study of sonro as mono- or combination therapy in patients (pts) with t(11;14)-posit...

Descrizione completa

Dettagli Bibliografici

Autori principali:	C. Cerchione, B. Dhakal, M. Hultcrantz, N. Nathwani, C.P. Venner, J. Lu, M.J. Slade, J.L. Kaufman, H. Chuah, C-K. Min, K. Kim, H. Cheng, A. Idoine, W. Zhang, X. Wang, A. Agarwal, H. Quach
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2025-09-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/12599
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!